Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.

Carin A Uyl-de GrootRachel RamsdenDawn LeeJanneke BoersmaSonja ZweegmanSujith Dhanasiri

Published in: European journal of haematology (2020)

Lenalidomide is cost-effective after ASCT vs no maintenance therapy in the Netherlands. By extending PFS, lenalidomide delays the cost burdens associated with relapse and subsequent treatment lines.

Keyphrases

stem cell transplantation
multiple myeloma
high dose
newly diagnosed
stem cells
cell therapy